Delivery Order SPE2DB22D9353-SPE2DB24FX2AG

Award Date 7/9/24
Potential Completion Date 7/10/24
Potential Value $78K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $25,868.10, is for the supply of XTANDI 40 MG CAPSULE 120S. The award is not associated with a set-aside program. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $33,923.76, is for the delivery of XTANDI 40 MG CAPSULE 120S over the period of September 10, 2024 to September 10, 2024. DMS Pharmaceutical Group Inc. holds a larger single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,622.72, is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to...
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,311.35 contract is for the delivery of XTANDI 40 MG CAPSULE 120S to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group Inc. holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. The delivery order is not associated with any set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,622.72, is for the delivery of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which allows the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order, valued at $8,622.72, is for the supply of XTANDI 40 MG CAPSULE 120S for the federal government. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $17,245.40 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of XTANDI 40 MG CAPSULE 120S, with a ceiling value of $4,311.35 and a period of performance through July 3, 2024. The award is a firm fixed-price delivery order. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $25,868.10, is for the supply of XTANDI 40 MG CAPSULE 120S, a branded pharmaceutical product. The contract is part of a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the DLA to...
  • SPE2DB22D9353
    Indefinite Delivery Contract
  • SPE2DB22D9353-SPE2DB24FX2AG
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $77,604.30, is for the delivery of XTANDI 40 MG CAPSULE 120S to support the recurring medical supply needs of military health facilities.

DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued up to $499,999,999, which allows the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items through December 31, 2025. This single-award vehicle, under the SPE2DB program, enables DMS Pharmaceutical Group to provide a vast array of medications, including both common and specialized pharmaceutical products, to support the diverse medical needs of military personnel and their dependents across various Department of Defense healthcare facilities. The current award is not associated with a set-aside designation.

Generated 10/8/24, 9:11 AM